NCT05745064View on ClinicalTrials.gov

A Study of TL-925 as a Treatment for Dry Eye Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

July 11, 2023

Study Completion Date

July 11, 2023

Conditions
Dry Eye Disease
Interventions
DRUG

TL-925

TL-925 is an eye drop.

DRUG

Placebo

The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.

Trial Locations (4)

46240

Michael Washburn Center for Ophthalmic Research, LLC., Indianapolis

80907

Vision Institute, Colorado Springs

92663

Aesthetic Eye Care, Newport Beach

01810

Andover Eye Associates, Andover

All Listed Sponsors
lead

Telios Pharma, Inc.

INDUSTRY

NCT05745064 - A Study of TL-925 as a Treatment for Dry Eye Disease | Biotech Hunter | Biotech Hunter